A Phase 3 clinical trial testing the experimental cancer vaccine galinpepimut-S (GPS) in people with acute myeloid leukemia (AML), a type of blood cancer,…
News
A new Phase 3 clinical trial has officially begun dosing patients to see if an experimental oral therapy can prevent the recurrence of pancreatic cancer…
VV169, an experimental cellular therapy being developed by Vyriad to treat myeloma, is expected to enter clinical testing in 2026, the…
PANCREATIC CANCER
Pancreatic cancer treatment atebimetinib set for Phase 3 trial
Immuneering is preparing to launch a Phase 3 clinical trial to test its experimental therapy, atebimetinib, in people with…
The first participant has been dosed in an early clinical trial testing the experimental radiation therapy Alpha DaRT in people with hard-to-treat glioma. The…
GYNECOLOGICAL CANCER
New targeted cancer therapy IDE034 heading to Phase 1 clinical trial
A Phase 1 clinical trial testing the experimental therapy IDE034 in people with various types of cancer, including gynecological cancers, is expected to start…
Johnson & Johnson (J&J) is asking the U.S. Food and Drug Administration (FDA) to approve a combination of two medications, Tecvayli (teclistamab) and…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SENTI-202, Senti Biosciences‘ experimental cell therapy being developed…
Treatment with the experimental medication eflornithine in combination with the approved chemotherapy Gleostine (lomustine) may help improve survival in people with aggressive astrocytoma carrying IDH…
GYNECOLOGICAL CANCER
Dosing begins in trial testing Enhertu for ovarian cancer
Dosing has begun in a Phase 3 clinical trial testing Enhertu (trastuzumab deruxtecan) as a maintenance treatment for certain people with ovarian cancer. The…
Recent Posts
- My husband and I aren’t just each other’s caregivers; we’re care partners
- Under-the-skin myeloma therapy shows strong responses in Phase 2 trial
- Trial finds treatment eases PV symptoms despite missing main goal
- The quiet courage of taking a short break as a caregiver
- EU clears Tecvayli as solo option when myeloma returns after first treatment